EMA welcomes political agreement on Critical Medicines Act

WHY IT MATTERS

Patients with rare diseases who depend on specific medicines may experience fewer shortages and more reliable access to their treatments if this act successfully strengthens European medicine supply chains.

The European Medicines Agency (EMA) announced that European lawmakers have agreed on a new Critical Medicines Act to make sure important medicines don't run out across Europe. This law was created because Europe has faced medicine shortages in recent years, especially during the COVID-19 pandemic and other global problems. The agreement aims to create stronger and more reliable ways to produce and deliver medicines that people need.

Source: European Medicines Agency (EMA) Description: EMA welcomes the provisional agreement reached by the European Parliament and the Council of the European Union on the proposed Critical Medicines Act (CMA), which represents an…, “At a time of increasing global disruptions, resilient and secure supply chains for critical medicines are essential to protect public health across the EU. Today’s…, In recent years, EU Member States have faced serious medicine shortages and global challenges such as the COVID-19 pandemic and geopolitical tensions hav Published: 2026-05-12T08:16:00.000Z Note: EMA announcements cover medicines approved in the EU. Orphan designations may not yet be available in the US.